A detailed history of Schonfeld Strategic Advisors LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 32,260 shares of XENE stock, worth $1.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
32,260
Previous 79,951 59.65%
Holding current value
$1.38 Million
Previous $3.44 Million 63.47%
% of portfolio
0.01%
Previous 0.02%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$36.25 - $43.75 $1.73 Million - $2.09 Million
-47,691 Reduced 59.65%
32,260 $1.26 Million
Q1 2024

May 15, 2024

SELL
$42.66 - $50.04 $322,040 - $377,751
-7,549 Reduced 8.63%
79,951 $3.44 Million
Q4 2023

Feb 14, 2024

SELL
$28.7 - $46.46 $3.2 Million - $5.18 Million
-111,484 Reduced 56.03%
87,500 $4.03 Million
Q3 2023

Nov 14, 2023

BUY
$34.16 - $39.73 $643,608 - $748,552
18,841 Added 10.46%
198,984 $6.8 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $4.18 Million - $5.22 Million
-119,976 Reduced 39.98%
180,143 $6.94 Million
Q1 2023

May 15, 2023

BUY
$33.46 - $40.35 $4.41 Million - $5.31 Million
131,706 Added 78.2%
300,119 $10.7 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $1.99 Million - $2.37 Million
60,129 Added 55.53%
168,413 $6.64 Million
Q3 2022

Nov 14, 2022

SELL
$30.79 - $39.82 $610,411 - $789,431
-19,825 Reduced 15.48%
108,284 $3.91 Million
Q2 2022

Aug 15, 2022

BUY
$25.44 - $35.16 $654,698 - $904,842
25,735 Added 25.14%
128,109 $3.9 Million
Q1 2022

May 16, 2022

BUY
$25.09 - $33.13 $338,062 - $446,393
13,474 Added 15.16%
102,374 $3.13 Million
Q4 2021

Feb 14, 2022

SELL
$15.6 - $35.4 $487,047 - $1.11 Million
-31,221 Reduced 25.99%
88,900 $2.78 Million
Q3 2021

Nov 16, 2021

BUY
$14.86 - $19.45 $349,522 - $457,483
23,521 Added 24.35%
120,121 $1.84 Million
Q2 2021

Aug 16, 2021

BUY
$16.81 - $20.0 $221,891 - $264,000
13,200 Added 15.83%
96,600 $1.8 Million
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $147,420 - $230,148
10,800 Added 14.88%
83,400 $1.49 Million
Q4 2020

Feb 16, 2021

BUY
$9.49 - $16.04 $94,900 - $160,400
10,000 Added 15.97%
72,600 $1.12 Million
Q3 2020

Nov 16, 2020

BUY
$10.82 - $13.35 $292,140 - $360,450
27,000 Added 75.84%
62,600 $1,000
Q2 2020

Aug 14, 2020

BUY
$10.21 - $14.9 $230,746 - $336,740
22,600 Added 173.85%
35,600 $447,000
Q1 2020

May 15, 2020

SELL
$8.08 - $17.57 $455,712 - $990,948
-56,400 Reduced 81.27%
13,000 $147,000
Q4 2019

Feb 14, 2020

BUY
$8.11 - $14.65 $562,834 - $1.02 Million
69,400 New
69,400 $910,000
Q2 2019

Aug 14, 2019

SELL
$8.51 - $10.75 $4.26 Million - $5.38 Million
-500,000 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$6.39 - $10.42 $63,529 - $103,595
9,942 Added 2.03%
500,000 $5.08 Million
Q4 2018

Feb 14, 2019

SELL
$5.61 - $12.62 $405,911 - $913,120
-72,355 Reduced 12.87%
490,058 $3.09 Million
Q3 2018

Nov 14, 2018

BUY
$9.0 - $14.9 $966,717 - $1.6 Million
107,413 Added 23.61%
562,413 $7.42 Million
Q2 2018

Aug 14, 2018

BUY
$4.8 - $9.2 $336,000 - $644,000
70,000 Added 18.18%
455,000 $4.19 Million
Q4 2017

Feb 14, 2018

BUY
$2.2 - $3.25 $242,000 - $357,500
110,000 Added 40.0%
385,000 $1.09 Million
Q3 2017

Nov 14, 2017

BUY
$2.45 - $3.25 $673,750 - $893,750
275,000
275,000 $811,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.66B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.